Stock Market News
AstraZeneca's leukaemia and breast cancer treatments make regulatory progress
AstraZeneca has reported regulatory progress in the US and Europe for treatments for a rare form of leukaemia and breast cancer.
The pharmaceutical company said the US Food and Drug Administration (FDA) had granted priority review to moxetumomab pasudotox - a potential new treatment for hairy cell leukaemia (HCL).
The immutoxin is intended for patients who have received at least two prior lines of therapy for HCL, a rare variety of leukaemia which affects about 1,000 people in the US each year. Though many patients respond initially to treatment up to 40% relapse.
"With no established standard of care and very few treatments available, there remains significant unmet medical need for people with relapsed or refractory HCL," AstraZeneca said.
AstraZeneca also said the European Medicines Agency had approved its marketing authorisation application for Lynparza, a treatment for breast cancer devised with Merck of the US. Lynparza was approved by the FDA in January and is available in almost 60 countries.
The pharmaceutical company said the US Food and Drug Administration (FDA) had granted priority review to moxetumomab pasudotox - a potential new treatment for hairy cell leukaemia (HCL).
The immutoxin is intended for patients who have received at least two prior lines of therapy for HCL, a rare variety of leukaemia which affects about 1,000 people in the US each year. Though many patients respond initially to treatment up to 40% relapse.
"With no established standard of care and very few treatments available, there remains significant unmet medical need for people with relapsed or refractory HCL," AstraZeneca said.
AstraZeneca also said the European Medicines Agency had approved its marketing authorisation application for Lynparza, a treatment for breast cancer devised with Merck of the US. Lynparza was approved by the FDA in January and is available in almost 60 countries.
Related share prices |
---|
AstraZeneca (AZN) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price